Revolution-Adjuvant Daraxonrasib vs SOC in resected PDAC (RASolute 304)

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
[RMC-6236-304] RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Principal Investigator
Headshot of Niharika Bansal Mettu
Associate Professor of Medicine
Protocol Number
IRB: PRO00119103
NCT: NCT07252232
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL